| ID Source | ID |
|---|---|
| PubMed CID | 54692915 |
| CHEMBL ID | 1533366 |
| CHEBI ID | 107506 |
| Synonym |
|---|
| smr000012636 |
| OPREA1_098010 |
| MLS000027148 , |
| 1-ethyl-4-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid (1h-benzoimidazol-2-yl)-amide |
| CHEBI:107506 |
| n-(1h-benzimidazol-2-yl)-1-ethyl-4-hydroxy-2-oxo-quinoline-3-carboxamide |
| 3-quinolinecarboxamide, n-1h-benzimidazol-2-yl-1-ethyl-1,2-dihydro-4-hydroxy-2-oxo- |
| n-(1h-benzimidazol-2-yl)-1-ethyl-2-hydroxy-4-oxoquinoline-3-carboxamide |
| AKOS005481537 |
| HMS2188F19 |
| n-(1h-benzimidazol-2-yl)-1-ethyl-4-hydroxy-2-keto-quinoline-3-carboxamide |
| cid_654742 |
| n-(1h-benzimidazol-2-yl)-1-ethyl-2-hydroxy-4-oxo-3-quinolinecarboxamide |
| bdbm31045 |
| n-(1h-benzimidazol-2-yl)-1-ethyl-2-hydroxy-4-keto-quinoline-3-carboxamide |
| n-(1h-benzimidazol-2-yl)-1-ethyl-2-oxidanyl-4-oxidanylidene-quinoline-3-carboxamide |
| CHEMBL1533366 |
| Q27185827 |
| n-(1h-benzimidazol-2-yl)-1-ethyl-4-hydroxy-2-oxo-3-quinolinecarboxamide |
| sr-01000314586 |
| SR-01000314586-1 |
| n-(1h-benzo[d]imidazol-2-yl)-1-ethyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamide |
| Class | Description |
|---|---|
| quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
| aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 2.7511 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 0.8913 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| Smad3 | Homo sapiens (human) | Potency | 15.8161 | 0.0052 | 7.8098 | 29.0929 | AID588855; AID720536; AID720537 |
| PINK1 | Homo sapiens (human) | Potency | 1.0000 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 2.8184 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 67.9K protein | Vaccinia virus | Potency | 1.0000 | 0.0001 | 8.4406 | 100.0000 | AID720580 |
| Parkin | Homo sapiens (human) | Potency | 1.0000 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
| IDH1 | Homo sapiens (human) | Potency | 7.3078 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 2.2387 | 0.0165 | 25.3078 | 41.3999 | AID602332 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 16.3601 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 50.1187 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 10.0000 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 63.3915 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| snurportin-1 | Homo sapiens (human) | Potency | 63.3915 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 14.5810 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 70.7946 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 10.0663 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 13.7782 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Vpr | Human immunodeficiency virus 1 | Potency | 39.8107 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 4.4668 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 3.1623 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 10.0000 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 19.9526 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 10.0000 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 11.2202 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 2.9402 | 0.0601 | 10.7453 | 37.9330 | AID485367; AID504636; AID504637 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PTK2B protein tyrosine kinase 2 beta | Homo sapiens (human) | IC50 (µMol) | 69.5000 | 1.5370 | 4.0805 | 6.9220 | AID1641 |
| XBP1 | Homo sapiens (human) | IC50 (µMol) | 7.9400 | 0.1600 | 5.4049 | 10.0000 | AID504313 |
| protein artemis isoform a | Homo sapiens (human) | IC50 (µMol) | 3.8100 | 1.5900 | 8.8278 | 17.9000 | AID720701 |
| sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | IC50 (µMol) | 39.5600 | 1.0810 | 2.6352 | 4.7700 | AID851; AID856 |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | IC50 (µMol) | 5.8400 | 0.1600 | 3.9959 | 10.0000 | AID504322 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| LAP4 | Saccharomyces cerevisiae (brewer's yeast) | EC50 (µMol) | 0.4500 | 0.4500 | 8.3714 | 33.0000 | AID2745 |
| RPL19A | Saccharomyces cerevisiae (brewer's yeast) | EC50 (µMol) | 3.2970 | 0.4200 | 5.5760 | 25.3600 | AID2740 |
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 1.0310 | 0.0600 | 8.9128 | 130.5170 | AID1902 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1667635 | Antibacterial activity against Streptococcus pneumoniae ATCC 700904 | 2020 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9 | Discovery of 4-hydroxy-2-oxo-1,2-dihydroquinolines as potential inhibitors of Streptococcus pneumoniae, including drug-resistant strains. |
| AID1667634 | Antibacterial activity against Streptococcus pneumoniae ATCC BAA1663 | 2020 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9 | Discovery of 4-hydroxy-2-oxo-1,2-dihydroquinolines as potential inhibitors of Streptococcus pneumoniae, including drug-resistant strains. |
| AID1667633 | Antibacterial activity against Streptococcus pneumoniae ATCC 49617 | 2020 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9 | Discovery of 4-hydroxy-2-oxo-1,2-dihydroquinolines as potential inhibitors of Streptococcus pneumoniae, including drug-resistant strains. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||